MedTrace Logo

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

NCT06551142 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 845

Last updated 2026-05-22

No results posted yet for this study

Summary

The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of Risvutatug rezetecan (Ris-Rez), also known as GSK5764227. The study will also see how the levels of Ris-Rez will change over time at different dose amounts when administered alone and in combination with other medicines like carboplatin, cisplatin, atezolizumab, pembrolizumab, durvalumab, bevacizumab, cetuximab, tarlatamab, dostarlimab

Conditions

  • Neoplasms

Interventions

BIOLOGICAL

Atezolizumab

Atezolizumab will be administered

BIOLOGICAL

Pembrolizumab

Pembrolizumab will be administered

BIOLOGICAL

Durvalumab

Durvalumab will be administered

BIOLOGICAL

Cetuximab

Cetuximab will be administered

BIOLOGICAL

Bevacizumab

Bevacizumab will be administered

BIOLOGICAL

Tarlatamab

Tarlatamab will be administered

BIOLOGICAL

Dostarlimab

Dostarlimab will be administered

BIOLOGICAL

Ris-Rez

Ris-Rez will be administered

DRUG

Cisplatin

Cisplatin will be administered

DRUG

Carboplatin

Carboplatin will be administered

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-30
Primary Completion
2028-10-16
Completion
2029-06-08
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Canada
  • France
  • Hong Kong
  • Israel
  • Italy
  • Japan
  • Panama
  • South Korea
  • Spain
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06551142 on ClinicalTrials.gov